Mayne Pharma’s net losses more than double
Carrie LaFrenzSenior reporter
Key Points
- Revenue ($m): 400.8, down 12pc from year-earlier 457.0
- Pre-tax profit ($m): -263.9 v year-earlier -135.4
- Net profit ($m): -209.1 v year-earlier -94.5
- Interim dividend: nil
Specialty pharmaceutical company Mayne Pharma Group said a weaker US dollar, COVID-19 and a tough US generics market has hurt the company, with sales and earnings down double digits in fiscal 2021.
Mayne Pharma CEO Scott Richards said growth drivers are the successful commercialisation of Nextstelllis in the US and Australia. Jesse Marlow
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles